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CorrespondenceDuffy Antigen Polymorphisms
Do Not Alter Progression of HIV
in African Americans
in the MACS CohortHe et al. recently reported the absence
of erythrocyte Duffy antigen/receptor for
chemokines (DARC) expression leads to
increased risk of acquiring HIV but slower
rates of disease progression (He et al.,
2008). We had also hypothesized DARC
may have a role in HIV pathogenesis and
progression by either influencing the
number of binding sites available to the
virus and its consequent distribution or by
acting as reservoir for chemokines, altering
the pattern of their release and thereby
decreasing in magnitude but prolonging in
duration the immune activation by which
DARC may influence HIV outcomes. To
investigate this, we identified the Duffy
genotype in African-American men from
the Multicenter AIDS Cohort Study
(MACS) and compared the time to AIDS
and death.
Sexually active homosexual or bisexual
men, without known AIDS, were recruited
as previously described (Kaslow et al.,
1987). From 5622 men enrolled before
2001, 295 HIV-infected African American
participantsweregenotyped.Thesequence
for the DARC polymorphisms of interest as
described by Tournamille et al. and the
primers were based on that reference
sequence (Tournamille et al., 1995).
Primary outcomes for analysis were
time from HIV-1 seroconversion to AIDS
and time to death. If seroconversion
occurred prior to recruitment in the study,
date of study entry was used as serocon-
version date, while, for those who sero-
converted during follow-up period, the
midpoint between the dates of last HIV-negative visit and first HIV-positive visit
was used.
Exposure was defined first on the basis
of erythrocyte promoter: those with the
null mutation in the erythrocyte promoter
are referred to as mutation type, where
those expressing Fy, regardless of open
reading frame (ORF) allele, are wild-type
(wt). Participants can therefore be grouped
as those who are homozygous for the null
mutation (mt/mt), those who are heterozy-
gous for the null mutation (mt/wt), or those
who are homozygous for the wild-type
(wt/wt). This analysis will reflect receptor
numbers on red blood cells, which is
proportional toa genedosageeffect (Wool-
ley et al., 2000). Second, groups or virtual
phenotypes are defined on the basis of
DARC expression, combining their ORF
allele (Fya or Fyb) with their erythrocyte
promoter mutation. This analysis reflects
the type of receptor on red blood cells.
The primary exposures in the analysis
are the promoter genotype, for which wt/
wt is the reference group. Covariates
controlled for in multivariate analysis
included calendar periods (before 1990
[reference group], 1990—1994, 1995—
1999, and post-2000), age at HIV-1 infec-
tion, and highly active antiretroviral therapy
(HAART) treatment experience prior to
events. Calendar period and HAART use
were treated as time-dependent covari-
ates. Cox proportional hazard regression
analysis models with time-dependent co-
variates were used to calculate the relative
hazard for predictors by using SAS 9.1
(SAS Institute). The assumptions of theCell Host & Microproportional hazards model were deemed
accurate based on the insignificant coeffi-
cient of the interaction term evaluating key
predictors and time that was obtained.
Kaplan-Meier curves were generated by
S-plus 8.1 (Insightful Corporation). An iden-
tical analysis was performed using
promoter and open reading frame haplo-
types, which reflect DARC phenotypes
(Fy is the reference group) as the primary
exposure.
In addition, the binomial test of propor-
tions was used to compare the frequency
distribution for DARC phenotype between
HIV antibody-positive men in this study to
a previously tested group of African-
American blood donors.
Of the 295 African-American men
included in this study, 249 were HIV posi-
tive at the time of recruitment to the study
(seroprevalent), and the remaining 46 se-
roconverted during follow-up. For the se-
roprevalent, the average age at studyentry
was 32.5 years old and median CD4+ T cell
counts 505 cells/mm3. For seroconvert-
ers, average age at seroconversion was
32.1 years and median CD4+ T cells was
588 cells/mm3 at the first HIV positive visit.
One hundred and seventy-four of the
participants (59.0%) were homozygous
for the erythrocyte promoter null mutation,
ninety-eight (33.2%) heterozygous, and
twenty-three (7.8%) had wt expression.
Predicted values were 169, 109, and 18
respectively (rounded to the nearest
integer). This distribution conforms to the
Hardy-Weinberg equation (p = 0.087
when tested for violation).
Overall, 104 developed AIDS (26 diag-
nosed before 1990, 52 diagnosed 1990–
1994, 23 diagnosed 1995–1999, and 3
diagnosed after 2000) and 141 died (19
died before 1990, 62 died 1990–1994,
50 died 1995–1999, and 10 died after
2000) as of March 31, 2007. Univariately,
time to AIDS or time to death did not differ
for the mt/mt and mt/wt groups comparedbe 5, May 21, 2009 ª2009 Elsevier Inc. 415
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CorrespondenceFigure 1. Kaplan-Meier Probability Curves of Time Free of AIDS for DARC Phenotypes
These show promoter genotypes in the left-hand panel and combined promoter and ORF genotypes in the right-hand panel. Differences did not reach statistical
significance.with the wt/wt group. Although there was
a suggestion that those with the mutation
had a worse prognosis (Figure 1A), this
difference was not statistically significant.
The trend, however, was in the opposite
direction to that which might have been
predicted on the basis of work from He
et al. (2008). Similarly, the survival curves
(Figure 1B) suggested that the FyaFyb
group had a better prognosis than the
Fy- group, and the Fya group had a
worse prognosis than the Fy, but these
differences did not reach statistical
significance.
Although the effect of erythroid pro-
moter mutations slightly increased after
accounting for calendar time, age, and
use of HAART, this was not statistically
significant when evaluating time to either
AIDS or death (Table 1). The relationships
observed with the DARC virtual phenotype
(ORF/promoter genotype combinations)
did not change when examined in a multi-416 Cell Host & Microbe 5, May 21, 2009 ªvariate model, or with analysis of the Fyb
genotype based on the promoter type
(wt/wt or wt/mt), i.e., whether the individual
was heterozygous or homozygous in their
expression of Fyb. In addition, the FyaFyb
wtwt group (n = 11 men, in which 1 man
developed AIDS) had a lower risk of devel-
oping AIDS when compared to the refer-
ence group Fy-: univariate hazard ratio
(HR) = 0.19, 95% CI: 0.03-1.40 (p =
0.104); multivariate HR = 0.18, 95% CI:
0.02-1.26 (p = 0.084).
We further conducted an analysis by re-
stricting events to 87 AIDS-related deaths
only (61.7% of all deaths), which gave
similar results (Table 1). When we treated
the 47 (33%) deaths of unknown causes
as nondeath outcomes but censored
them in the analysis, the results remained
unchanged (data not shown).
To determinewhether any virtual pheno-
type (a defined combination of promoter
and ORF genotypes) was overrepresented2009 Elsevier Inc.in the cohort studied, we compared the
frequency distribution of virtual pheno-
types to the phenotypic frequency in
African Americans cited in standard texts
(AABB, 1999). The frequency distribution
of virtual phenotypes for the HIV-1-in-
fected men were significantly different
from that of the non-HIV-infected cohort,
suggesting a possible difference in HIV
acquisition risk, but in the direction oppo-
site to that which may have been antici-
pated by the findings of He et al. (2008).
Respectively, the values were for Fy nega-
tive expression (Fy ab) 59% (174
patients) versus 68% in the blood donor
population (p < 0.001), for Fya expression
(Fy a+b) 1% (2 patients) versus 9% in
the blood donor population (p < 0.001),
Fyb expression (Fy ab+) 24% (70 pa-
tients) versus 22% in the blood donor
population (p = NS), and for expression of
both antigens (Fy a+b+) 17% (49 patients)
versus 1% (p < 0.001).Table 1. Multivariate Analysis of Time to AIDS, Death, and AIDS-Related Death (Expressed as Hazard Ratios)
Time to AIDS Time to Death Time to AIDS-Related Death
Erythroid Promoter Mutations
wt/wt 1 1 1
mt/mt 1.42 (95% CI 0.65–3.11) p = 0.38 1.59 (95% CI 0.80–3.17) p = 0.18 1.72 (95% CI 0.69–4.32) p = 0.25
mt/wt 1.42 (95% CI 0.63–3.22) p = 0.40 1.48 (95% CI 0.72–3.03) p = 0.29 1.67 (95% CI 0.64–4.32) p = 0.29
ORF/Promoter Genotype Combinations
Fy 1 1 1
Fya 1.34 (95% CI 0.189.75) p = 0.77 2.29 (95% CI 0.569.41) p = 0.25 1.53 (95% CI 0.2111.22) p = 0.68
FyaFyb 0.75 (95% CI 0.421.34) p = 0.33 0.75 (95% CI 0.461.22) p = 0.25 0.79 (95% CI 0.431.45) p = 0.44
Fyb 1.06 (95% CI 0.671.67) p = 0.80 0.90 (95% CI 0.601.36) p = 0.63 0.93 (95% CI 0.561.56) p = 0.79
Fyb_mtwt 0.99 (95% CI 0.611.63) p = 0.97 0.96 (95% CI 0.631.47) p = 0.86 0.97 (95% CI 0.571.66) p = 0.91
Fyb_wtwt 1.50 (95% CI 0.603.74) p = 0.39 0.57 (95% CI 0.181.80) p = 0.34 0.76 (95% CI 0.242.46) p = 0.65
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CorrespondenceThe study has several limitations. The
cohort size is small but well described.
The power is limited at 0.3 when
comparing the proportion of any observed
mutation to the expected one. Some poly-
morphisms, such as Fyb weak (0% in
some cohorts of African origin) (Olsson
et al., 1998) have not been tested for.
Linkage disequilibrium, due to some
known or unknown gene with an influence
on HIV progression on chromosome 1
(Pogo and Chaudhuri, 2000) has not
been completely excluded but might be
expected to be seen to be in the same
direction in all studies of African Ameri-
cans.
Our results appear discordant to those of
He et al. (2008). There are several potential
reasons for this. We compared the time
from HIV infection to AIDS and to death
on the basis of genotype, while they as-
sessed survival over time on the basis of
ethnic origin and genotype. Furthermore,
the number of patients assessed is signifi-
cantlygreater in their study.While our study
populations were from different U.S.
states, there are unlikely to be any major
genetic differences in the groups studied
on this basis. On the other hand, our find-
ings are supported to those recently re-
ported at a conference in a South African
population (Julg et al., 2009), and repro-
duction of the findings in multiple cohorts
is likely to be the best test of validity. Why
the results are discordant is not clear.
One issue may be the choice of ancestry
markers in the study of He et al. Those
chosen are associated with HIV biology;
however, the distribution of the markers in
HIV-positive and -negative African Ameri-
cans was reported to be similar.
DARC is upregulated in inflammatory
states, including transplant rejection, otherforms of crescentic glomerulonephritis,
vasculitis, and arthritis (Bruhl et al., 2005;
Patterson et al., 2002). In all of these studies,
DARC is associated with endothelial rather
than red cell expression. Polymorphisms in
the red cell promoter have not been shown
to alter endothelial expression of this
protein. Despite evidence that DARC on
redcells isable tobindchemokines, thereby
altering in vitro and in vivo chemokine levels,
there is limited evidence that this phenom-
enon alters outcomes in disease. This study
supports the hypothesis that altered eryth-
rocyte expression of DARC has minimal
impact on HIV disease progression.
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